Cargando…
Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome
Angelman syndrome is a neurodevelopmental disorder caused by deficiency of the maternally inherited UBE3A gene in neurons. Antisense oligonucleotide therapies are under development to reinstate UBE3A protein production. Non-invasive biomarkers to detect target engagement and treatment response are n...
Autores principales: | Spencer, Elizabeth R., Shi, Wen, Komorowski, Robert W., Gilbert, James P., Ostrowski, Lauren M., Bird, Lynne M., Thibert, Ronald, Bao, Channa, Molloy, Fiona, Calhoun, Michael, Koirala, Samir, Jafar-nejad, Paymaan, Rigo, Frank, Kramer, Mark A., Chu, Catherine J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123847/ https://www.ncbi.nlm.nih.gov/pubmed/35611307 http://dx.doi.org/10.1093/braincomms/fcac106 |
Ejemplares similares
-
Delta power robustly predicts cognitive function in Angelman syndrome
por: Ostrowski, Lauren M., et al.
Publicado: (2021) -
Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome
por: Lee, Dongwon, et al.
Publicado: (2023) -
Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model
por: Milazzo, Claudia, et al.
Publicado: (2021) -
Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration
por: Gould, Stacey Anne, et al.
Publicado: (2021) -
Antisense oligonucleotide therapy for KCNT1 encephalopathy
por: Burbano, Lisseth Estefania, et al.
Publicado: (2022)